Rexahn Pharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:RNN)

$1.99 -0.05 (-2.45 %)
(As of 12/12/2017 04:00 PM ET)
Previous Close$2.04
Today's Range$1.96 - $2.08
52-Week Range$1.30 - $7.10
Volume432,543 shs
Average Volume442,256 shs
Market Capitalization$65.34 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.65

About Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Rexahn Pharmaceuticals logoRexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Receive RNN News and Ratings via Email

Sign-up to receive the latest news and ratings for RNN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:RNN
CUSIPN/A
Phone+1-240-2685300

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.93)
Net IncomeN/A
Net MarginsN/A
Return on Equity-26.84%
Return on Assets-15.81%

Miscellaneous

EmployeesN/A
Outstanding Shares31,730,000

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Frequently Asked Questions

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "RNN."

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) issued its quarterly earnings results on Monday, August, 8th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.01. View Rexahn Pharmaceuticals' Earnings History.

When will Rexahn Pharmaceuticals make its next earnings announcement?

Rexahn Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for Rexahn Pharmaceuticals.

Where is Rexahn Pharmaceuticals' stock going? Where will Rexahn Pharmaceuticals' stock price be in 2017?

5 Wall Street analysts have issued 1 year price objectives for Rexahn Pharmaceuticals' stock. Their predictions range from $13.00 to $19.50. On average, they anticipate Rexahn Pharmaceuticals' stock price to reach $16.50 in the next twelve months. View Analyst Ratings for Rexahn Pharmaceuticals.

Are investors shorting Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals saw a drop in short interest in November. As of November 30th, there was short interest totalling 1,842,747 shares, a drop of 16.6% from the November 15th total of 2,209,414 shares. Based on an average daily volume of 373,735 shares, the short-interest ratio is presently 4.9 days. Approximately 5.9% of the shares of the stock are short sold.

Who are some of Rexahn Pharmaceuticals' key competitors?

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the folowing people:

  • Peter C. Brandt, Independent Chairman of the Board (Age 59)
  • Peter D. Suzdak Ph.D., Chief Executive Officer, Director (Age 57)
  • Tae Heum Jeong, Chief Financial Officer, Secretary (Age 45)
  • Ely Benaim, Chief Medical Officer (Age 55)
  • Charles G. Beever, Independent Director (Age 63)
  • Mark P. Carthy, Independent Director (Age 55)
  • Kwang Soo Cheong Ph.D., Independent Director (Age 55)
  • Richard J. Rodgers, Independent Director (Age 50)

Who owns Rexahn Pharmaceuticals stock?

Rexahn Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Zurcher Kantonalbank Zurich Cantonalbank (0.16%). View Institutional Ownership Trends for Rexahn Pharmaceuticals.

Who bought Rexahn Pharmaceuticals stock? Who is buying Rexahn Pharmaceuticals stock?

Rexahn Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Zurcher Kantonalbank Zurich Cantonalbank. View Insider Buying and Selling for Rexahn Pharmaceuticals.

How do I buy Rexahn Pharmaceuticals stock?

Shares of Rexahn Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rexahn Pharmaceuticals' stock price today?

One share of Rexahn Pharmaceuticals stock can currently be purchased for approximately $1.99.

How big of a company is Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals has a market capitalization of $65.34 million.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 Shady Grove Rd Ste 455, ROCKVILLE, MD 20850-7203, United States. The company can be reached via phone at +1-240-2685300.


MarketBeat Community Rating for Rexahn Pharmaceuticals (RNN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  166 (Vote Outperform)
Underperform Votes:  110 (Vote Underperform)
Total Votes:  276
MarketBeat's community ratings are surveys of what our community members think about Rexahn Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.50$16.50$17.83$13.69
Price Target Upside: 754.92% upside754.92% upside583.27% upside314.77% upside

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Consensus Price Target History

Price Target History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
11/6/2017HC WainwrightReiterated RatingBuy$19.50View Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$13.00View Rating Details
8/7/2017Ifs SecuritiesReiterated RatingOutperformView Rating Details
6/9/2017Rodman & RenshawReiterated RatingBuy$19.50View Rating Details
6/1/2017FBR & CoReiterated RatingOutperform$30.00 -> $14.00View Rating Details
2/29/2016Roth CapitalReiterated RatingBuy$1.75View Rating Details
(Data available from 12/12/2015 forward)

Earnings

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Earnings History and Estimates Chart

Earnings by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018($0.14)N/AView Earnings Details
8/8/2016Q216($0.02)($0.01)ViewN/AView Earnings Details
5/9/2016Q116($0.02)($0.02)ViewN/AView Earnings Details
11/3/2015Q315($0.03)($0.02)ViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.02)ViewN/AView Earnings Details
4/6/2015($0.03)($0.01)ViewN/AView Earnings Details
3/17/2015($0.02)($0.02)ViewN/AView Earnings Details
11/14/2014($0.03)($0.02)ViewN/AView Earnings Details
8/14/2014Q214($0.02)($0.02)ViewN/AView Earnings Details
3/25/2014($0.06)($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20171($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)
Institutional Ownership by Quarter for Rexahn Pharmaceuticals (NYSEAMERICAN:RNN)

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/10/2017Chang Ho AhnDirectorSell250,000$0.70$175,000.00View SEC Filing  
1/12/2015Chang Ho AhnDirectorSell314,656$0.91$286,336.96View SEC Filing  
1/12/2015Tae Heum JeongCFOSell317,272$0.91$288,717.52View SEC Filing  
6/12/2014Chang Ho AhnDirectorSell136,193$0.99$134,831.07View SEC Filing  
9/9/2013Tae Heum JeongCFOSell71,139$0.46$32,723.94View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) News Headlines

Source:

SEC Filings

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Rexahn Pharmaceuticals (NYSEAMERICAN RNN) Stock Chart for Tuesday, December, 12, 2017

Loading chart…

This page was last updated on 12/12/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.